HAVANA — Cuba’s Soberana 2 vaccine candidate has shown 62% efficacy with just two of its three doses, state-run biopharmaceutical corporation BioCubaFarma said on Saturday, citing preliminary data from late phase trials.
Cuba, whose biotech sector has exported vaccines for decades, has five vaccine candidates in clinical trials, of which two – Soberana 2 and Abdala – are in late phase trials.
“In a few weeks we should have the results for the efficacy with three doses which we expect will be superior,” said Vicente Vrez, director of the state-run Finlay Vaccine Institute, which developed Soberana 2.
The news comes as the Caribbean’s largest island is facing its wo…
Keep on reading: Cuba encouraged by early efficacy results of homegrown COVID-19 vaccine